Search results for "Candida Glabrata"

showing 10 items of 21 documents

Evaluation of a novel chromogenic medium for Candida spp. identification and comparison with CHROMagar™ Candida for the detection of Candida auris in…

2020

Abstract A shift to Candida non-albicans infections has been noted during the last years, and the emergence of multi-resistant Candida auris has complicated their management. The aim of this study was first to compare the performance of the novel chromogenic medium CHROMagar™ Candida Plus (CHROMagar, France) with CHROMagar™ Candida (Becton Dickinson, Germany) for the presumptive identification of Candida species; and then, to evaluate its utility in the detection of C. auris in surveillance samples. CHROMagar™ Candida Plus showed a good performance compared with the reference medium CHROMagar™ Candida. Sensitivity and specificity were 100% in both media for tested species at 48 h of incubat…

0301 basic medicineMicrobiology (medical)030106 microbiologySensitivity and SpecificityMicrobiology03 medical and health sciencesfluids and secretions0302 clinical medicineHumans030212 general & internal medicineMycological Typing TechniquesCandidaCandida glabratabiologyChromogenicCandida lusitaniaeBecton dickinsonCandidiasisGeneral Medicinebacterial infections and mycosesequipment and suppliesbiology.organism_classificationCulture MediaInfectious DiseasesCandida aurisChromogenic CompoundsCandida sppChromagar candidaDiagnostic microbiology and infectious disease
researchProduct

In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species

2016

Objectives: To evaluate the in vitro activity of anidulafungin combined with amphotericin B or voriconazole against Candida spp. biofilms. Methods: Four Candida albicans, four Candida tropicalis, four Candida glabrata, two Candida parapsilosis and two Candida orthopsilosis blood isolates were tested by the microdilution chequerboard method combined with the XTT metabolic assay. Biofilm MIC was defined as the lowest concentration producing 50% metabolic inhibition with respect to control (BMIC50). Concentrations in the combinations ranged from 1/8xBMIC(50) to 4xBMIC(50) found for each antifungal tested alone. Results: Anidulafungin plus amphotericin B acted synergistically against C. albican…

0301 basic medicineMicrobiology (medical)Antifungal Agents030106 microbiologyMicrobial Sensitivity TestsCandida parapsilosisAnidulafunginMicrobiologyCandida tropicalis03 medical and health sciencesEchinocandinsAmphotericin BAmphotericin BmedicineHumansPharmacology (medical)Candida albicansCandidaPharmacologyVoriconazolebiologyCandida glabrataChemistryCandidemiaDrug Synergismbiology.organism_classificationbacterial infections and mycosesCorpus albicansInfectious DiseasesBiofilmsAnidulafunginVoriconazolemedicine.drug
researchProduct

Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on …

2017

Abstract Introduction The study objective was to evaluate the efficacy of different dosages of caspofungin in the treatment of invasive candidiasis and aspergillosis, in relation to the probability of pharmacokinetic/pharmacodynamic (PK/PD) target attainment, using modelling and Monte Carlo simulations in critically ill adult patients on continuous haemodiafiltration. Methods Critically ill adult patients on continuous venovenous haemodiafiltration treated with caspofungin were analysed. A population PK model was developed. Four caspofungin dosing regimens were simulated: the licensed regimen, 70 mg/day, 100 mg/day or 200 mg/day. A PK/PD target was defined as the ratio between the area unde…

0301 basic medicineMicrobiology (medical)MaleAntifungal AgentsCandida parapsilosisCritical Illness030106 microbiologyPopulationCandida glabrataHemodiafiltrationMicrobial Sensitivity TestsPharmacologyAspergillosis03 medical and health scienceschemistry.chemical_compoundEchinocandinsLipopeptides0302 clinical medicinePharmacokineticsCaspofunginCandida albicansMedicineHumansPharmacology (medical)Candidiasis Invasive030212 general & internal medicineDosingeducationAgedAged 80 and overInvasive Pulmonary Aspergillosiseducation.field_of_studyMaintenance dosebusiness.industryCandidiasisGeneral MedicineMiddle Agedmedicine.diseaseRegimenInfectious DiseasesAspergilluschemistryPharmacodynamicsFemaleCaspofunginbusinessInternational journal of antimicrobial agents
researchProduct

Multilocus microsatellite analysis of European and African Candida glabrata isolates

2016

This study aimed to elucidate the genetic relatedness and epidemiology of 127 clinical and environmental Candida glabrata isolates from Europe and Africa using multilocus microsatellite analysis. Each isolate was first identified using phenotypic and molecular methods and subsequently, six unlinked microsatellite loci were analyzed using automated fluorescent genotyping. Genetic relationships were estimated using the minimum-spanning tree (MStree) method. Microsatellite analyses revealed the existence of 47 different genotypes. The fungal population showed an irregular distribution owing to the over-representation of genetically different infectious haplotypes. The most common genotype was …

0301 basic medicineSettore MED/07 - Microbiologia E Microbiologia ClinicaClonal complexEpidemiologyMultilocus microsatellite analysisCandida glabrataMolecular phylogenyGene locusCentral typeRelated genotypeGenotypeEnvironmental MicrobiologyHaplotypeDNA FungalPriority journalGeneticsAlleleCandidiasisGeneral MedicineClassificationEuropePhenotypeInfectious DiseasesCandida Glabrata; Adhesins; FluconazoleCandidiasiMicrosatelliteMicrosatellite RepeatMicrobiological examinationHumanMicrobiology (medical)GenotypeSettore MED/17 - Malattie InfettiveMicrosatellite DNA030106 microbiologyBiologyEuropeanMicrobiologyArticle03 medical and health sciencesGenetic variationMicrosatellite repeatsGeneticsHumansAlleleGenotypingAllelesScience & TechnologyCandida glabrataMicrosatellite markerHaplotypeAfricanGenetic Variationbiology.organism_classificationNonhuman030104 developmental biologyFungal DNAHaplotypesIsolation and purificationGenetic LociAfricaMultilocus sequence typingFungus isolationGenetic variabilityMicrosatellite genotypeMultilocus Sequence Typing
researchProduct

The intestinal mycobiota and its relationship with overweight, obesity and nutritional aspects

2021

[Background]: The fungal community of the gastrointestinal tract has recently become of interest, and knowledge of its relationship with the development of obesity is scarce. The present study aimed to evaluate the cultivable fungal fraction from the microbiota and to analyze its relationship with obesity.

AdultMale0301 basic medicineColony Count MicrobialMedicine (miscellaneous)030209 endocrinology & metabolismOverweightCandida parapsilosis03 medical and health sciences0302 clinical medicineWeight lossYeastsCandida kruseimedicineHumansObesityFood scienceCandida albicansCandida030109 nutrition & dieteticsNutrition and DieteticsbiologyCandida glabratabusiness.industryFungiDiscriminant AnalysisRhodotorulaOverweightbiology.organism_classificationmedicine.diseaseObesityGastrointestinal TractSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationFemalemedicine.symptombusinessWeight gainMycobiome
researchProduct

Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.

2009

ABSTRACT Two large studies compared posaconazole and fluconazole or itraconazole for prophylaxis in subjects undergoing allogeneic hematopoietic stem cell transplantation or subjects with acute myelogenous leukemia. To assess the impact of prophylaxis on colonization and the development of resistance in Saccharomyces yeasts, identification and susceptibility testing were performed with yeasts cultured at regular intervals from mouth, throat, and stool samples. Prior to therapy, 34 to 50% of the subjects were colonized with yeasts. For all three drugs, the number of positive Candida albicans cultures decreased during drug therapy. In contrast, the proportion of subjects with positive C. glab…

AdultMalePosaconazoleAntifungal AgentsAdolescentItraconazoleCandida glabrataMicrobial Sensitivity TestsClinical TherapeuticsMicrobiologyYoung AdultCandida albicansmedicineHumansPharmacology (medical)Candida albicansFluconazoleMycosisPhylogenyAgedCandidaPharmacologychemistry.chemical_classificationbiologyCandida glabrataCandidiasisMiddle AgedTriazolesmedicine.diseasebiology.organism_classificationCorpus albicansInfectious DiseaseschemistryImmunologyAzoleFemaleItraconazoleFluconazolemedicine.drugAntimicrobial agents and chemotherapy
researchProduct

Peptides of the Constant Region of Antibodies Display Fungicidal Activity

2012

Synthetic peptides with sequences identical to fragments of the constant region of different classes (IgG, IgM, IgA) of antibodies (Fc-peptides) exerted a fungicidal activity in vitro against pathogenic yeasts, such as Candida albicans, Candida glabrata, Cryptococcus neoformans, and Malassezia furfur, including caspofungin and triazole resistant strains. Alanine-substituted derivatives of fungicidal Fc-peptides, tested to evaluate the critical role of each residue, displayed unaltered, increased or decreased candidacidal activity in vitro. An Fc-peptide, included in all human IgGs, displayed a therapeutic effect against experimental mucosal and systemic candidiasis in mouse models. It is in…

Antifungal AgentsErythrocyteslcsh:MedicineImmunoglobulin Gchemistry.chemical_compoundEchinocandinsMiceCaspofunginCandida albicanslcsh:ScienceCandida albicansMice Inbred BALB CMultidisciplinarybiologyCandidiasisAnimal ModelsInfectious DiseasesMedicineFemaleMalasseziaImmunoglobulin Constant RegionsResearch ArticleImmunologyMycologyMicrobial Sensitivity TestsMicrobiologyHemolysisAntibodiesMicrobiologyLipopeptidesImmune systemModel OrganismsDrug Resistance FungalmedicineAnimalsHumansBiologyCryptococcus neoformansMalasseziaCandida glabratalcsh:RImmunityTriazolesbiology.organism_classificationmedicine.diseaseImmunoglobulin ADisease Models AnimalchemistryImmunoglobulin MImmunoglobulin Gbiology.proteinCryptococcus neoformanslcsh:QSystemic candidiasisCaspofunginPeptidesPLoS ONE
researchProduct

Steroidal saponins from Smilax medica and their antifungal activity.

2005

Three new steroidal saponins (1-3) were isolated from the roots of Smilax medica, together with the known disporoside A (4). The structures of the new compounds were elucidated mainly by extensive spectroscopic analysis (1D and 2D NMR, FABMS, and HRESIMS). Compounds 1, 2, and 4 demonstrated weak antifungal activity against the human pathogenic yeasts Candida albicans, C. glabrata, and C.tropicalis, with MIC values between 12.5 and 50 microg/mL.

Antifungal AgentsStereochemistrySaponinPharmaceutical ScienceMicrobial Sensitivity TestsPharmacognosyAnalytical ChemistryDrug DiscoveryHumansCandida albicansMexicoNuclear Magnetic Resonance BiomolecularCandidaPharmacologychemistry.chemical_classificationPlants MedicinalbiologyTraditional medicineCandida glabrataMolecular StructureLiliaceaeOrganic ChemistrySmilaxGlycosideBiological activitySaponinsbiology.organism_classificationComplementary and alternative medicinechemistrySmilaxMolecular MedicineSteroidsJournal of natural products
researchProduct

Candida glabrata meningitis and endocarditis: a late severe complication of candidemia

2014

SummaryWe report an unusual case of Candida glabrata meningitis and endocarditis in a young Caucasian woman with a prosthetic aortic valve and suffering from a dissecting thoraco-abdominal aortic aneurysm. C. glabrata was isolated from culture of the cerebrospinal fluid. Candida infection of the central nervous system is an uncommon manifestation of disseminated infection due to Candida species. Our case report also highlights the intrinsic resistance of C. glabrata to azoles.

Aortic valveMicrobiology (medical)AdultSettore MED/07 - Microbiologia E Microbiologia Clinicamedicine.medical_specialtySettore MED/17 - Malattie InfettiveIntrinsic resistanceCandida glabrataBiologylcsh:Infectious and parasitic diseasesAortic aneurysmCerebrospinal fluidmedicineEndocarditisHumanslcsh:RC109-216MeningitisSevere complicationCandida glabrataEndocarditisCandidemiaGeneral Medicinemedicine.diseasebiology.organism_classificationbacterial infections and mycosesSurgeryMeningitis Fungalmedicine.anatomical_structureInfectious Diseasescardiovascular systemFemaleCandida glabrata Candidemia Meningitis EndocarditisMeningitisInternational Journal of Infectious Diseases
researchProduct

Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy) pyrazole derivatives

2011

The antibacterial and antifungal activity of a series of products, in which the 1,5-dimethyl-4-(cyano- NNO-azoxy)pyrazol-3-yl and 1,3-dimethyl-4-(cyano-NNO-azoxy)pyrazol-5-yl moieties were linked to pyridine, pyrazole, isoxazole, thiophene and the furan ring, were examined. No molecule displayed activity against the Gram-negative bacteria tested. Conversely, some compounds displayed activity against two Staphylococcus aureus strains, including the methicillin resistant strain. All compounds displayed interesting antifungal activity, the most active compound of the series being the thiophene derivative 7a. This compound’s activity against Candida krusei and Candida glabrata (MIC = 0.25 and 0…

AzoxyStaphylococcus aureusAntifungal AgentsStereochemistryClinical BiochemistryPharmaceutical ScienceMicrobial Sensitivity TestsPyrazoleBiochemistryChemical synthesisAntifungal activity Pyrazole Azole sistance Cyano-NNO-azoxy Thiophenechemistry.chemical_compoundAnti-Infective AgentsThiopheneCandida kruseiNitrilesDrug DiscoveryThiopheneAntifungal activityIsoxazoleAntifungal activity; Pyrazole; Azole resistance; Cyano-NNO-azoxy; Thiophene.Molecular BiologyCandidaMolecular StructurebiologyCandida glabrataOrganic ChemistryBiological activitybiology.organism_classificationSettore CHIM/08 - Chimica FarmaceuticachemistryCyano-NNO-azoxyPyrazoleAzole resistancePyrazolesMolecular MedicineAzo Compounds
researchProduct